Unknown PHASE2 INTERVENTIONAL 1-arm NCT01284946

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Porphyria Cutanea Tarda

Interventions Exjade

Updated 4 times since 2017 Last updated: Jan 26, 2011 Started: Jan 31, 2011 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Porphyria Cutanea Tarda, this trial is ongoing. The trial is conducted by Assistance Publique - Hôpitaux de Paris and has accumulated 4 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris
Association pour l'Etude des Fonctions Digestives (AEFD)

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Colombes, France